Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:26:16.110Z.
Calculation as of: 2026-10-06T16:26:16.110Z.
Quote observation: 2026-10-06T16:24:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c88c4f39e0f2b8ce509c05ad310ef4a925915372bb385716b1b31bbca6f45484
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | $29.51M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.88M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $29.64M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.60M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.17M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.46M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.23M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $30.69M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.63M | N/A | N/A | N/A | N/A |
| Nortech Systems Incorporated (NSYS)vs › | $31.44M | N/A | 0.06 | 0.04 | 0.04 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute